- Home
- UROY vs AQST Comparison
UROY vs AQST Comparison
Compare UROY & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- AQST
- Stock Information
- Founded
- UROY 2017
- AQST 2004
- Country
- UROY Canada
- AQST United States
- Employees
- UROY N/A
- AQST N/A
- Industry
- UROY
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- AQST Health Care
- Exchange
- UROY Nasdaq
- AQST Nasdaq
- Market Cap
- UROY 336.8M
- AQST 390.4M
- IPO Year
- UROY N/A
- AQST 2018
- Fundamental
- Price
- UROY $3.27
- AQST $5.42
- Analyst Decision
- UROY Strong Buy
- AQST Strong Buy
- Analyst Count
- UROY 2
- AQST 6
- Target Price
- UROY $4.00
- AQST $10.67
- AVG Volume (30 Days)
- UROY 2.7M
- AQST 2.5M
- Earning Date
- UROY 07-16-2025
- AQST 11-03-2025
- Dividend Yield
- UROY N/A
- AQST N/A
- EPS Growth
- UROY N/A
- AQST N/A
- EPS
- UROY N/A
- AQST N/A
- Revenue
- UROY $11,285,840.00
- AQST $44,132,000.00
- Revenue This Year
- UROY $228.36
- AQST N/A
- Revenue Next Year
- UROY N/A
- AQST $38.71
- P/E Ratio
- UROY N/A
- AQST N/A
- Revenue Growth
- UROY N/A
- AQST N/A
- 52 Week Low
- UROY $1.43
- AQST $2.12
- 52 Week High
- UROY $3.34
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- UROY 66.60
- AQST 80.05
- Support Level
- UROY $3.05
- AQST $3.73
- Resistance Level
- UROY $3.34
- AQST $4.00
- Average True Range (ATR)
- UROY 0.17
- AQST 0.26
- MACD
- UROY 0.04
- AQST 0.13
- Stochastic Oscillator
- UROY 91.57
- AQST 96.57
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.